Global Markets Direct’s, ‘Renal Cell Carcinoma – Pipeline Review, H2 2015′, provides an overview of the Renal Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 7
Renal Cell Carcinoma Overview 8
Therapeutics Development 9
Renal Cell Carcinoma - Therapeutics under Development by Companies 11
Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 19
Renal Cell Carcinoma - Pipeline Products Glance 20
Renal Cell Carcinoma - Products under Development by Companies 24
Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34
Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35
Renal Cell Carcinoma - Therapeutics Assessment 128
Drug Profiles 151
Renal Cell Carcinoma - Recent Pipeline Updates 450
Renal Cell Carcinoma - Dormant Projects 685
Renal Cell Carcinoma - Discontinued Products 698
Renal Cell Carcinoma - Product Development Milestones 702
Appendix 710

List of Tables

Number of Products under Development for Renal Cell Carcinoma, H2 2015 25
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2015 26
Number of Products under Development by Companies, H2 2015 28
Number of Products under Development by Companies, H2 2015 (Contd..1) 29
Number of Products under Development by Companies, H2 2015 (Contd..2) 30
Number of Products under Development by Companies, H2 2015 (Contd..3) 31
Number of Products under Development by Companies, H2 2015 (Contd..4) 32
Number of Products under Development by Companies, H2 2015 (Contd..5) 33
Number of Products under Development by Companies, H2 2015 (Contd..6) 34
Number of Products under Investigation by Universities/Institutes, H2 2015 35
Comparative Analysis by Late Stage Development, H2 2015 36
Comparative Analysis by Clinical Stage Development, H2 2015 37
Comparative Analysis by Early Stage Development, H2 2015 38
Comparative Analysis by Unknown Stage Development, H2 2015 39
Products under Development by Companies, H2 2015 40
Products under Development by Companies, H2 2015 (Contd..1) 41
Products under Development by Companies, H2 2015 (Contd..2) 42
Products under Development by Companies, H2 2015 (Contd..3) 43
Products under Development by Companies, H2 2015 (Contd..4) 44
Products under Development by Companies, H2 2015 (Contd..5) 45
Products under Development by Companies, H2 2015 (Contd..6) 46
Products under Development by Companies, H2 2015 (Contd..7) 47
Products under Development by Companies, H2 2015 (Contd..8) 48
Products under Development by Companies, H2 2015 (Contd..9) 49
Products under Investigation by Universities/Institutes, H2 2015 50
Renal Cell Carcinoma - Pipeline by AbbVie Inc., H2 2015 51
Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015 52
Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2015 53
Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2015 54
Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H2 2015 55
Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2015 56
Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 57
Renal Cell Carcinoma - Pipeline by arGEN-X BV, H2 2015 58
Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2015 59
Renal Cell Carcinoma - Pipeline by Arrowhead Research Corporation, H2 2015 60
Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2015 61
Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2015 62
Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H2 2015 63
Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2015 64
Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2015 65
Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2015 66
Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 67
Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2015 68
Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 69
Renal Cell Carcinoma - Pipeline by Caladrius Biosciences, Inc. , H2 2015 70
Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2015 71
Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015 72
Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 73
Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2015 74
Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2015 75
Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015 76
Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H2 2015 77
Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 78
Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2015 79
Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015 80
Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015 81
Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 82
Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2015 83
Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 84
Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2015 85
Renal Cell Carcinoma - Pipeline by GenSpera, Inc., H2 2015 86
Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015 87
Renal Cell Carcinoma - Pipeline by Hetero Drugs Limited, H2 2015 88
Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2015 89
Renal Cell Carcinoma - Pipeline by Hospira, Inc., H2 2015 90
Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2015 91
Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H2 2015 92
Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2015 93
Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2015 94
Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2015 95
Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 96
Renal Cell Carcinoma - Pipeline by InteRNA Technologies B.V., H2 2015 97
Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H2 2015 98
Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 99
Renal Cell Carcinoma - Pipeline by KineMed, Inc., H2 2015 100
Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 101
Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2015 102
Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2015 103
Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H2 2015 104
Renal Cell Carcinoma - Pipeline by MediGene AG, H2 2015 105
Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015 106
Renal Cell Carcinoma - Pipeline by Medivation, Inc., H2 2015 107
Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015 108
Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2015 109
Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 110
Renal Cell Carcinoma - Pipeline by Mologen AG, H2 2015 111
Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H2 2015 112
Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2015 113
Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H2 2015 114
Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2015 115
Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2015 116
Renal Cell Carcinoma - Pipeline by Omeros Corporation, H2 2015 117
Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015 118
Renal Cell Carcinoma - Pipeline by OncoMax, H2 2015 119
Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 120
Renal Cell Carcinoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 121
Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015 122
Renal Cell Carcinoma - Pipeline by Panacela Labs, Inc., H2 2015 123
Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2015 124
Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2015 125
Renal Cell Carcinoma - Pipeline by PharmaEssentia Corporation, H2 2015 126
Renal Cell Carcinoma - Pipeline by Pono Pharma, H2 2015 127
Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2015 128
Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H2 2015 129
Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 130
Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2015 131
Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2015 132
Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 133
Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 134
Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 135
Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015 136
Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H2 2015 137
Renal Cell Carcinoma - Pipeline by Theravectys SA, H2 2015 138
Renal Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 139
Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 140
Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2015 141
Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2015 142
Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2015 143
Assessment by Monotherapy Products, H2 2015 144
Assessment by Combination Products, H2 2015 145
Number of Products by Stage and Target, H2 2015 147
Number of Products by Stage and Mechanism of Action, H2 2015 157
Number of Products by Stage and Route of Administration, H2 2015 164
Number of Products by Stage and Molecule Type, H2 2015 166
Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015 466
Renal Cell Carcinoma - Dormant Projects, H2 2015 701
Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2015 702
Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2015 703
Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2015 704
Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2015 705
Renal Cell Carcinoma - Dormant Projects (Contd..5), H2 2015 706
Renal Cell Carcinoma - Dormant Projects (Contd..6), H2 2015 707
Renal Cell Carcinoma - Dormant Projects (Contd..7), H2 2015 708
Renal Cell Carcinoma - Dormant Projects (Contd..8), H2 2015 709
Renal Cell Carcinoma - Dormant Projects (Contd..9), H2 2015 710
Renal Cell Carcinoma - Dormant Projects (Contd..10), H2 2015 711
Renal Cell Carcinoma - Dormant Projects (Contd..11), H2 2015 712
Renal Cell Carcinoma - Dormant Projects (Contd..12), H2 2015 713
Renal Cell Carcinoma - Discontinued Products, H2 2015 714
Renal Cell Carcinoma - Discontinued Products (Contd..1), H2 2015 715
Renal Cell Carcinoma - Discontinued Products (Contd..2), H2 2015 716
Renal Cell Carcinoma - Discontinued Products (Contd..3), H2 2015 717

List of Figures

Number of Products under Development for Renal Cell Carcinoma, H2 2015 25
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2015 26
Number of Products under Development by Companies, H2 2015 27
Number of Products under Investigation by Universities/Institutes, H2 2015 35
Comparative Analysis by Late Stage Development, H2 2015 36
Comparative Analysis by Clinical Stage Development, H2 2015 37
Comparative Analysis by Early Stage Products, H2 2015 38
Assessment by Monotherapy Products, H2 2015 144
Assessment by Combination Products, H2 2015 145
Number of Products by Top 10 Targets, H2 2015 146
Number of Products by Stage and Top 10 Targets, H2 2015 146
Number of Products by Top 10 Mechanism of Actions, H2 2015 156
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 156
Number of Products by Top 10 Routes of Administration, H2 2015 163
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 163
Number of Products by Top 10 Molecule Types, H2 2015 165
Number of Products by Stage and Top 10 Molecule Types, H2 2015 165